{"name":"Daiichi Sankyo Co., Ltd.","slug":"daiichi-sankyo-co-ltd","ticker":"","exchange":"","domain":"daiichisankyo.co.jp","description":"","hq":"Chūō","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"DU-176b (edoxaban)","genericName":"DU-176b (edoxaban)","slug":"du-176b-edoxaban","indication":"Atrial fibrillation for stroke prevention","status":"phase_3"},{"name":"CS-3150","genericName":"CS-3150","slug":"cs-3150","indication":"Hypertension","status":"phase_3"},{"name":"olmesartan medoxomil and a CCB","genericName":"olmesartan medoxomil and a CCB","slug":"olmesartan-medoxomil-and-a-ccb","indication":"Hypertension","status":"marketed"},{"name":"olmesartan medoxomil and a diuretic","genericName":"olmesartan medoxomil and a diuretic","slug":"olmesartan-medoxomil-and-a-diuretic","indication":"Hypertension","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CPT-11 based regimens","genericName":"CPT-11 based regimens","slug":"cpt-11-based-regimens","indication":"Metastatic colorectal cancer","status":"phase_2"},{"name":"DS-8201a","genericName":"DS-8201a","slug":"ds-8201a","indication":"HER2-positive metastatic breast cancer","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"DS-5565","genericName":"DS-5565","slug":"ds-5565","indication":"Neuropathic pain","status":"phase_3"},{"name":"DU-176b tablets","genericName":"DU-176b tablets","slug":"du-176b-tablets","indication":"Major depressive disorder","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Alendronate sodium hydrate","genericName":"Alendronate sodium hydrate","slug":"alendronate-sodium-hydrate","indication":"Osteoporosis in postmenopausal women","status":"phase_3"},{"name":"DS-5141b","genericName":"DS-5141b","slug":"ds-5141b","indication":"Other","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"CS-8958","genericName":"CS-8958","slug":"cs-8958","indication":"Acute uncomplicated influenza A and B infection in adults and children","status":"phase_3"}]}],"pipeline":[{"name":"CPT-11 based regimens","genericName":"CPT-11 based regimens","slug":"cpt-11-based-regimens","phase":"phase_2","mechanism":"CPT-11 is a topoisomerase I inhibitor that works by stabilizing the cleavage complex of DNA and RNA, thereby inhibiting DNA replication and transcription.","indications":["Metastatic colorectal cancer","Metastatic non-small cell lung cancer"],"catalyst":""},{"name":"DS-5565","genericName":"DS-5565","slug":"ds-5565","phase":"phase_3","mechanism":"DS-5565 is a selective sodium channel inhibitor that reduces neuronal excitability by blocking voltage-gated sodium channels.","indications":["Neuropathic pain","Diabetic peripheral neuropathic pain"],"catalyst":""},{"name":"DU-176b (edoxaban)","genericName":"DU-176b (edoxaban)","slug":"du-176b-edoxaban","phase":"phase_3","mechanism":"Edoxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation.","indications":["Atrial fibrillation for stroke prevention","Deep vein thrombosis and pulmonary embolism treatment and prevention","Acute coronary syndrome"],"catalyst":""},{"name":"Alendronate sodium hydrate","genericName":"Alendronate sodium hydrate","slug":"alendronate-sodium-hydrate","phase":"phase_3","mechanism":"Alendronate sodium inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite on the bone surface and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.","indications":["Osteoporosis in postmenopausal women","Osteoporosis in men","Glucocorticoid-induced osteoporosis","Paget's disease of bone"],"catalyst":""},{"name":"CS-3150","genericName":"CS-3150","slug":"cs-3150","phase":"phase_3","mechanism":"CS-3150 is a non-steroidal mineralocorticoid receptor (MR) antagonist that blocks aldosterone signaling to reduce sodium retention and blood pressure.","indications":["Hypertension","Heart failure with preserved ejection fraction (HFpEF)"],"catalyst":""},{"name":"CS-8958","genericName":"CS-8958","slug":"cs-8958","phase":"phase_3","mechanism":"CS-8958 is a neuraminidase inhibitor that prevents influenza virus release from infected cells by blocking sialic acid cleavage.","indications":["Acute uncomplicated influenza A and B infection in adults and children"],"catalyst":""},{"name":"DS-5141b","genericName":"DS-5141b","slug":"ds-5141b","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DS-8201a","genericName":"DS-8201a","slug":"ds-8201a","phase":"phase_3","mechanism":"DS-8201a is an anti-HER2 antibody-drug conjugate that delivers a cytotoxic payload directly to HER2-expressing cancer cells.","indications":["HER2-positive metastatic breast cancer","HER2-low metastatic breast cancer","HER2-positive gastric cancer"],"catalyst":""},{"name":"DU-176b tablets","genericName":"DU-176b tablets","slug":"du-176b-tablets","phase":"phase_2","mechanism":"DU-176b tablets are a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain.","indications":["Major depressive disorder","Generalized anxiety disorder"],"catalyst":""},{"name":"olmesartan medoxomil and a CCB","genericName":"olmesartan medoxomil and a CCB","slug":"olmesartan-medoxomil-and-a-ccb","phase":"marketed","mechanism":"This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through dual vasodilation and reduced vascular resistance.","indications":["Hypertension"],"catalyst":""},{"name":"olmesartan medoxomil and a diuretic","genericName":"olmesartan medoxomil and a diuretic","slug":"olmesartan-medoxomil-and-a-diuretic","phase":"marketed","mechanism":"Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while the diuretic component enhances sodium and water excretion to further reduce fluid volume and blood pressure.","indications":["Hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQNE9rb0hlUG9RLVNiR3NmVHdJajRMc09SR01Zekxaa1RfQ3pmTm5HMVkzTVdGVkNpMFFCQjNmdU1LYjF5NEp4Q3pyVHlQMjRfZkpKSGlacEIwUkpiLVh6S0dWME5hTFRnVEh3WEl3ZFN5a1BPTy1OMGprR08yc3E4VWlzM1RMUU5lSGRUb0QtWjJzd3NiMEg5NkxaUEtjck5kYmwyeA?oc=5","date":"2026-04-02","type":"regulatory","source":"IndexBox","summary":"Guardant Health Stock Rises on Japan Regulatory News for Daiichi Sankyo Drug - News and Statistics - IndexBox","headline":"Guardant Health Stock Rises on Japan Regulatory News for Daiichi Sankyo Drug - News and Statistics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPWlhxVFlJbExCTXNwWDNmdnVxRUsyVmNBdXI1dlMwdnlYX3V4YjEwMENmanp6ek5SZmxNOFFsU1dLLXptdG1KemFlZEp5MlFoa1FVek41bkhnZWh3cEVzM3JOdzd4aEVjSGFDTTRTcF9CaW00YVlnU2tGeUFjQlhya05FS1VuVEI1ejhHb29RYktrWTVfZl8tV0t1S0Y2N1oxOGNkTGpvSzZ4NU1QaURXeFByeFdRUXVWUDRsSHRuWWI?oc=5","date":"2026-03-29","type":"pipeline","source":"AD HOC NEWS","summary":"Daiichi Sankyo Co Ltd Stock: Oncology Focus and Global Expansion Drive Long-Term Investor Interest J - AD HOC NEWS","headline":"Daiichi Sankyo Co Ltd Stock: Oncology Focus and Global Expansion Drive Long-Term Investor Interest J","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOVVpMQXl5eDdqOFo0d2tOT3hWR3k0N2kyX2pDVldaUUk3NTVnWlp0WEpUR2FGbGFjUW5EXzhaZzFUeEdIdG9NbnpqbXB5cF9nbTROeFl3T2F4bUd3dkQzQW1wQ3ZHaU9xWTkyN3Uwcm41b29pZjBkd1ZNaEpJbWFfVS1rMld2bDhPT1JZVEtaOGJGN3N1UlU1ZURaa1kwa1dBYno2RHNDTW9wNGZ3ajJtZnBvd0prNDg?oc=5","date":"2026-03-23","type":"regulatory","source":"London South East","summary":"Daiichi Sankyo's cancer drug approved as second-line therapy in Japan - London South East","headline":"Daiichi Sankyo's cancer drug approved as second-line therapy in Japan","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQVm4yUEp1QnpHNTVfSmE4cUNsN2J2MkVtMkRoOHdkRDg3dkdWNmlHa2loei1NTUwzR0VfYkdOd0taQlA2YWVueTZGa2NDM0NBZTNEa0c2U0dkZ2JTU2t2eXlKVDZheGpzaHpqM3RIN2U3THNUQzJtSy11d3JDNHQ2OGF0cXR6cDZqSUp2R2tIcVA5bHROWkh2ZkZEQW96NzVsRlRBaXNFa1MzX3JwRjdqdDhOLTFOYmx0RUxqbA?oc=5","date":"2026-03-16","type":"pipeline","source":"AD HOC NEWS","summary":"Daiichi Sankyo Co Ltd Stock (ISIN: JP3475350009) Faces Headwinds Amid Oncology Pipeline Pressures - AD HOC NEWS","headline":"Daiichi Sankyo Co Ltd Stock (ISIN: JP3475350009) Faces Headwinds Amid Oncology Pipeline Pressures","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-02","type":"pipeline","source":"simplywall.st","summary":"Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year - simplywall.st","headline":"Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxPNHE3VzhENW5xREVUelpqdk5Ra1loY2Q0eTBSdlRJVlJwUUxoRFZVRVU2bmJTNVZZNjN3YnZVZWZkYXZXd3ZHclVmbmlTUlYyUU82WEtvM2lGbjJkZXUzNlVxNk90N1pfcUpjU2RYRTZLQy1CZE5PZG4tVXl1YU4yTlBaa1dnUXZHTFBDalhsZDNsMTZkNDZWc0c1d19tY2hCOE5jVzRFT3p3LXZIV0VSWUdwZ3p1bGtjb3ZkcWFxU1R5TzBOckYxMk9BVQ?oc=5","date":"2025-12-15","type":"regulatory","source":"reuters.com","summary":"AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment - reuters.com","headline":"AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE02c0dLekdtUzNOdjA1ZTB5V2pZbkhHWUI0ZHk0MHdsdEROZU05UHhKZjI3aDJYUXNQUzBndGd1Skt1M2JBS1hHTnIzOVRkUzAweW53Mm9LM09PWWd1Q3lsM2JNenE?oc=5","date":"2025-09-16","type":"deal","source":"아시아경제","summary":"Vibozone Pharmaceuticals Signs Partnership Agreement with Daiichi Sankyo Korea for \"Anapraju\" - 아시아경제","headline":"Vibozone Pharmaceuticals Signs Partnership Agreement with Daiichi Sankyo Korea for \"Anapraju\" - 아시아경제","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQc3p0ZlRjNl9oZTl1cjVwWGVaMWt3WmlQdVZZaFRhOHFaUzdFZTV5MjljUDZwWk1wa295bHhQS2hKWVg2dXd1bnZsYkV1elZrNERjbXlMV2lnczF5NjI0R1d0MVIzTHl0cWJjZjg0SjFtWDdPYmQ3SjdvLUt1cVpMT2psWGVrZW51YTIwUV9MeHNkNEtSYmhGMWZpOU5UbDZ6Y1BqWjZrZThuYWxsQk9nSTdxT2JQdkxYQWM0RV9ZUFFaQ0NxV1dzQmxsbWdIMWU5UlFwZzRJQlhYSVNkUFhQNC0yZw?oc=5","date":"2025-06-16","type":"regulatory","source":"BioSpace","summary":"VANFLYTA® is Now Approved in Canada Specifically for Adult Patients with Newly Diagnosed FLT3-ITD Positive AML - BioSpace","headline":"VANFLYTA® is Now Approved in Canada Specifically for Adult Patients with Newly Diagnosed FLT3-ITD Positive AML","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOOXI3R3VfcEJ5WUEtemxSbHNDb0V1d3V0UFBMS1JLTzhQUVY0ZlNienZoc0NIN3l4SW9rdjVqV01LdGVORWZleHZzaEE2T0xNYU9HSUJnejItb3liaXd1ZWtqZW5ScWc1aWJRYjJhMXVDYnA1M1c0Z0FpRWJSV1hzcDlDeEdVN2VPNmFPRjVfY1pKZmp3NzQ5eDJsS1JGZ3RleHg5dEFKMlliN1JwU1pBYmhqR3dOYTBLR1pxYXl6X0ZPRWZvVDNNOGZfbXZyUzRzTXc?oc=5","date":"2025-05-29","type":"pipeline","source":"reuters.com","summary":"Merck, Daiichi pull US application for 'guided missile' therapy for lung cancer - reuters.com","headline":"Merck, Daiichi pull US application for 'guided missile' therapy for lung cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPck45QXM4dEswQkhjLXY2WTc1YWZmVTJ4dkNPcnd6N2I1ZTZUTDNQcWRHQTJ3am0xY3JTOXJwQ3Mxb3F3d2JCZTRLYU1FVV9ud2pIOUwyQ2pyZTQ0SkVKMWl0Qmc2aUFkQW5WWndlemg2b2VQbHpqWkgxeGc2bk4zbDZGb0R3dHo0bTlYVWw3RmdkdE82N2I0U2lwMkZXdGc?oc=5","date":"2025-04-11","type":"pipeline","source":"Seeking Alpha","summary":"Daiichi Sankyo: Good Diversification Tool For U.S. Investors - Seeking Alpha","headline":"Daiichi Sankyo: Good Diversification Tool For U.S. Investors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxPZWY0aXZMb0ZRUFVfN1o3VkZHd3UxeG42RUdCbC1EZVhiSTNHbTQ3VXNwZGp4Si1nQ0R4UWswblNLVlAxbFB5Qkh3RVRPVFJrLU1EZUYtelE2M1VmNzhOWXlWUFBaYVVwVGV6UG5MemRkVHFqZ2lYbzZkZnJUNmJjbzZwakg3NzhReU95Vzd1OVpQS1RuZktKNDB1R2lmWjdUUHlRcmZOWkFCeHdpd2FNU1E4TUNNTU9RTnpLQW5uSk9kbUxzaldydzZQbU02dGN4bW0zRVJ4VHF1clZGdS1ub093ZUZJZVdiYWduQmF3SVJaYnBhQTZpMTM1a3RhcGMtdzNxeDJjM2pVTU1ELWtWS0ZPakFGTnF6?oc=5","date":"2022-12-21","type":"pipeline","source":"PR Newswire","summary":"Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging - PR Newswire","headline":"Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxObFQtWXlrY1k0ZDFuMmZEQ3JaYWE4b05seWMtQ2QtOXpYRDdrOU15VWpqZFVfNm00YTdJdHplcXhPdkp4bjRUUkdVNHoxeWxNMkpralN6MEZwdGpGZXRmRTRWUWVTYWx6LUE0VmF1eEVyeUgzVmJCNUpQMUwtT0NIaWtpeFUyX194R3ZKMUFpaHJ0bDBrWWdOTDFVX0cwU2szLVV0UmNINDBtUDVFMUV0dkZpaUFBMGVnOHI0UUFWVm5iNXpmaWtqc2FDblV3UGFTaW1rSHo3dkJlSHd6UkR3YlgtRlpLSEU4NGl5aHpzd2JNdEdJYTVWTl9n?oc=5","date":"2019-03-28","type":"deal","source":"AstraZeneca","summary":"AstraZeneca and Daiichi Sankyo enter collaboration for novel HER2-targeting antibody-drug conjugate - AstraZeneca","headline":"AstraZeneca and Daiichi Sankyo enter collaboration for novel HER2-targeting antibody-drug conjugate","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"phase_2":3,"phase_3":6,"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}